Legend Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Legend Biotech has a total shareholder equity of $1.0B and total debt of $314.8M, which brings its debt-to-equity ratio to 31.1%. Its total assets and total liabilities are $1.7B and $701.7M respectively.
Key information
31.13%
Debt to equity ratio
US$314.80m
Debt
| Interest coverage ratio | n/a |
| Cash | US$992.59m |
| Equity | US$1.01b |
| Total liabilities | US$701.69m |
| Total assets | US$1.71b |
Recent financial health updates
Recent updates
Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade
Aug 14Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money
Aug 04
There's Reason For Concern Over Legend Biotech Corporation's (NASDAQ:LEGN) Massive 32% Price Jump
Jun 14
Expanding Facilities In Belgium And New Jersey Will Boost Reach
Expanded manufacturing and outpatient approval are set to increase supply and streamline distribution, potentially boosting net margins and revenue.Legend Biotech's Carvykti Is Taking Off, And It's Still Early (Rating Upgrade)
Mar 11Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)
Jan 07Some Legend Biotech Corporation (NASDAQ:LEGN) Shareholders Look For Exit As Shares Take 26% Pounding
Jan 02Legend Biotech: The Story Brightens
Dec 05Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Sep 18Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges
Jul 30Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
May 14Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)
Mar 15Legend Biotech: Solid Traction With Carvykti Rollout
Jan 29Legend Biotech wins approval of Carvykti for multiple myeloma in Japan
Sep 27Legend Biotech stock slides on proposed ADS offering
Jul 25Legend Biotech ends Phase 1 trial for lymphoma candidate
Jul 07Financial Position Analysis
Short Term Liabilities: LEGN's short term assets ($1.2B) exceed its short term liabilities ($433.6M).
Long Term Liabilities: LEGN's short term assets ($1.2B) exceed its long term liabilities ($268.1M).
Debt to Equity History and Analysis
Debt Level: LEGN has more cash than its total debt.
Reducing Debt: LEGN's debt to equity ratio has increased from 0% to 31.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LEGN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if LEGN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/16 12:29 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Legend Biotech Corporation is covered by 30 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |